Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Scientists discover protective role of retinoic acid against intestinal inflammation

Scientists at Trinity College Dublin have made novel discoveries around the protective influence of Vitamin A against the damaging immune responses that lead to inflammatory bowel disease.

5 Jun 2013

UC researchers identify biomarkers for inflammatory bowel disease

Using the Department of Defense Serum Repository, University of Cincinnati researchers have identified a number of biomarkers for inflammatory bowel disease, which could help with earlier diagnosis and intervention in those who have not yet shown symptoms.

22 May 2013

IBD patients are at higher risk of melanoma, report researchers

Patients with inflammatory bowel disease (IBD) are at higher risk of melanoma, a form of skin cancer, report researchers at Mayo Clinic. Researchers found that IBD is associated with a 37 percent greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in Orlando, Fla.

21 May 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has initiated the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for the treatment of pediatric Crohn's disease.

15 May 2013

Study says influenza immunization is safe in children with IBD

Influenza immunization rates in children with inflammatory bowel disease (IBD) are low despite its safety according to a new study by researchers at the Institute for Clinical Evaluative Sciences (ICES), Children's Hospital of Eastern Ontario (CHEO), the Ottawa Hospital Research Institute (OHRI), and the University of Ottawa.

7 May 2013

PET/CT may enhance detection of inflammatory bowel diseases in the future

Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, may be detected and monitored more effectively in the future with positron emission tomography/computed tomography, according to research published in the May issue of The Journal of Nuclear Medicine.

2 May 2013

Study: Biologic response modifying drugs can cause acute liver injury

A commonly used class of biologic response modifying drugs can cause acute liver injury with elevated liver enzymes, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

30 Apr 2013

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

The tiny thymus teaches the immune system to ignore the teeming, foreign bacteria in the gut that helps you digest and absorb food, researchers say.

30 Apr 2013

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Researchers have newly associated nine genetic regions with a rare autoimmune disease of the liver known as primary sclerosing cholangitis (PSC). This brings the total number of genetic regions associated with the disease to 16.

22 Apr 2013

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

BioLineRx, a biopharmaceutical development company, announced today positive Phase IIa results for BL-7040, an orally available drug for treating inflammatory bowel disease.

17 Apr 2013

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Santarus, Inc. and Pharming Group NV today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration to obtain marketing approval for RUCONEST (recombinant human C1 esterase inhibitor) 50 U/kg, an investigational drug for the treatment of acute angioedema attacks in patients with hereditary angioedema.

17 Apr 2013

Researchers use atomic force microscopy technique to read information encoded in gut lining

A new technique based on atomic force microscopy was developed at the Institute of Food Research to help 'read' information encoded in the gut lining.

15 Apr 2013

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

Lipid Therapeutics announces today that it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed with a planned Phase III trial in the US in mild-moderate ulcerative colitis patients. The LT-02 IND was subject to the FDA's customary 30 day review period.

11 Apr 2013

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

A Spectrum Health clinical trial has found that fecal microbial transplantation (FMT) has resulted in the improvement or absence of symptoms in most pediatric patients with active ulcerative colitis.

7 Apr 2013

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Ulcerative colitis (UC) and Crohn’s disease (CD) are both relapsing and remitting chronic diseases of bowel inflammation. By that I mean they flare and physicians try to get the flare under control and try to induce remission. However, despite a number of treatments available, they tend to relapse.

From Takeda 3 Apr 2013

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Scientists discover protective role of retinoic acid against intestinal inflammation

UC researchers identify biomarkers for inflammatory bowel disease

IBD patients are at higher risk of melanoma, report researchers

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Soligenix starts first clinical study for development of SGX203 for pediatric Crohn's disease

Study says influenza immunization is safe in children with IBD

PET/CT may enhance detection of inflammatory bowel diseases in the future

Study: Biologic response modifying drugs can cause acute liver injury

Researchers say tiny thymus teaches immune system to ignore foreign bacteria in gut

Genetic study defines link between primary sclerosing cholangitis and other autoimmune diseases

Phase IIa study shows safety and efficacy of BL-7040 in treating ulcerative colitis

Santarus, Pharming Group submit Biologics License Application to FDA for RUCONEST

Researchers use atomic force microscopy technique to read information encoded in gut lining

Lipid Therapeutics to proceed with US LT-02 Phase III trial for mild-moderate ulcerative colitis

FMT treatment improves symptoms in pediatric patients with active ulcerative colitis

Ulcerative colitis and Crohn’s disease treatments: an interview with Dr Parikh, vice president, general medicine, Takeda

Researchers identify link between immune response and blood clotting

LabCorp launches expanded IBD testing profile

Experts outline new agenda for inflammatory bowel disease research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in